Desogestrel (DSG) and Corifollitropin(FSH-CTP) Alfa for Ovarian Stimulation in Donors
Status:
Withdrawn
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Currently, controlled ovarian stimulation (COS) in oocyte donors is performed by daily
injections of gonadotropins( recombinant FSH) plus a GnRH Antagonist usually form 5th-6th
stimulation day until ovulation induction with a bolus of another injection of a
gonadotropin-releasing hormone (GnRH) Agonist. Injections of the GnRH Antagonist avoid
untimely luteinizing hormone (LH) surge and spontaneous ovulation prior to follicular
aspiration. There is a preparation of long-acting recombinant follicle stimulating hormone
(rFSH= (corifollitropin alfa (FSH-CTP), Elonva®, MSD), that allows that a single subcutaneous
injection substitutes the first 7 days of daily gonadotropin injections. On the other hand, a
contraceptive oral progesterone only( Desogestrel, DSG) is available for contraception,
avoiding the LH surge. It has been described the usefulness of orally administered
medroxyprogesterone acetate, 10 mg to inhibit the endogenous LH surge in IVF patients during
COS.
In donors, by administering a single injection of FSH-CTP and oral desogestrel since the
first menstruation day, the total number of injections administered is reduced and less
discomfort is experienced without adverse impact on ovarian response. No description of the
hormonal and ovarian response under this protocol has been published